Biomarkers for evaluation of treatment response in classical Hodgkin lymphoma: comparison of sGalectin-1, sCD163 and sCD30 with TARC

The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

(2014) A. Gallamini et al.   HAEMATOLOGICA

Circulating galectin-1 concentrations in systemic sclerosis: potential contribution to digital vasculopathy

(2014) Koichi Yanaba et al.   International Journal of Rheumatic Diseases

Role of Imaging in the Staging and Response Assessment of Lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group

(2014) Sally F. Barrington et al.   JOURNAL OF CLINICAL ONCOLOGY

In Vivo Treatment Sensitivity Testing With Positron Emission Tomography/Computed Tomography After One Cycle of Chemotherapy for Hodgkin Lymphoma

(2014) Martin Hutchings et al.   JOURNAL OF CLINICAL ONCOLOGY

Omitting Radiotherapy in Early Positron Emission Tomography–Negative Stage I/II Hodgkin Lymphoma Is Associated With an Increased Risk of Early Relapse: Clinical Results of the Preplanned Interim Analysis of the Randomized EORTC/LYSA/FIL H10 Trial

(2014) John M.M. Raemaekers et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Soluble CD163 as a Marker of Macrophage Activity in Newly Diagnosed Patients with Multiple Sclerosis

(2014) Morten Stilund et al.   PLoS One

Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma

(2013) J. Ouyang et al.   BLOOD

Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer

(2013) L Bracci et al.   CELL DEATH AND DIFFERENTIATION

Prognostic Significance of Pretreatment Serum Cytokines in Classical Hodgkin Lymphoma

(2013) P. R. Marri et al.   CLINICAL CANCER RESEARCH

FDG-PET Response–adapted Therapy

(2013) Martin Hutchings   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Altered galectin-1 serum levels in patients diagnosed with high-grade glioma

(2013) Tina Verschuere et al.   JOURNAL OF NEURO-ONCOLOGY

The Macrophage-Specific Serum Marker, Soluble CD163, Is Increased in Obesity and Reduced After Dietary-Induced Weight Loss

(2013) Karen Fjeldborg et al.   Obesity

The microenvironment in classical Hodgkin lymphoma: An actively shaped and essential tumor component

(2013) Yuxuan Liu et al.   SEMINARS IN CANCER BIOLOGY

Hodgkin lymphoma: 2012 update on diagnosis, risk-stratification, and management

(2012) Stephen M. Ansell   AMERICAN JOURNAL OF HEMATOLOGY

Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma

(2012) Maike Sauer et al.   AMERICAN JOURNAL OF HEMATOLOGY

Serum CD163 and TARC as Disease Response Biomarkers in Classical Hodgkin Lymphoma

(2012) K. Jones et al.   CLINICAL CANCER RESEARCH

Hodgkin lymphoma

(2012) Ralf Küppers et al.   JOURNAL OF CLINICAL INVESTIGATION

Plasma thymus and activation-regulated chemokine as an early response marker in classical Hodgkin's lymphoma

(2011) W. J. Plattel et al.   HAEMATOLOGICA

Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22

(2008) Marijke Niens et al.   BRITISH JOURNAL OF HAEMATOLOGY

Serum Galectin-1 and Galectin-3 Levels in Benign and Malignant Nodular Thyroid Disease

(2008) Sven Saussez et al.   THYROID

The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy

(2007) Sven Saussez et al.   ORAL ONCOLOGY